Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).

被引：11
|
作者：
Jones, Jeffrey Alan
Robak, Tadeusz
Wach, Malgorzata
Brown, Jennifer R.
Menter, Alexander R.
Vandenberghe, Elizabeth
Ysebaert, Loic
Wagner-Johnston, Nina D.
Polikoff, Jonathan
Awan, Farrukh Tauseef
Badoux, Xavier Camille Albert
Coutre, Steven
Spurgeon, Stephen Edward Forbes
Loscertales, Javier
Dreiling, Lyndah
Xing, Guan
Peterman, Sissy
Dubowy, Ronald L.
Flinn, Ian
Owen, Carolyn
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[2] Med Univ Lodz, Lodz, Poland
[3] Med Univ Lublin, Lublin, Poland
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Kaiser Permanente Med Grp, Denver, CO USA
[6] St James Hosp, Dublin, Ireland
[7] CHU Toulouse, Toulouse, France
[8] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[9] Kaiser Hosp San Diego, San Marcos, CA USA
[10] St George Hosp, Cammeray, Australia
[11] Stanford Univ, Stanford, CA 94305 USA
[12] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[13] Hosp Univ La Princesa, Madrid, Spain
[14] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[15] Sarah Cannon Res Inst, Hematol Malignancies Res Program, Nashville, TN USA
[16] Alberta Hlth Serv, Calgary, AB, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7515
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7515
引用
收藏
页数：2
相关论文
共 50 条
  • [1] UPDATED RESULTS OF A PHASE 3 RANDOMIZED, CONTROLLED STUDY OF IDELALISIB IN COMBINATION WITH OFATUMUMAB FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Robak, T.
    Jones, J.
    Wach, M.
    Brown, J.
    Menter, A.
    Vandenberghe, E.
    Ysebaert, L.
    Wagner-Johnston, N.
    Polikoff, J.
    Awan, F.
    Badoux, X.
    Coutre, S.
    Spurgeon, S.
    Loscertales, J.
    Xing, G.
    Dubowy, R.
    Flinn, I.
    Owen, C.
    HAEMATOLOGICA, 2016, 101 : 53 - 53
  • [2] Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL)
    Jones, Jeffrey Alan
    Wach, Malgorzata
    Robak, Tadeusz
    Brown, Jennifer R.
    Menter, Alexander R.
    Vandenberghe, Elizabeth
    Ysebaert, Loic
    Wagner-Johnston, Nina D.
    Polikoff, Jonathan
    Salman, Huda S.
    Taylor, Kerry McDonald
    Coutre, Steven
    Spurgeon, Stephen Edward Forbes
    Kendall, Stephan Disean
    Flinn, Ian
    Dreiling, Lyndah
    Dubowy, Ronald
    Cho, Yoonjin
    Peterman, Sissy
    Owen, Carolyn
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).
    Flinn, Ian
    Kimby, Eva
    Cotter, Finbarr E.
    Giles, Francis J.
    Janssens, Ann
    Pulczynski, Elisa Jacobsen
    Ysebeart, Loic
    Pluta, Andrzej
    Marco, Jose Antonio Garcia
    Taylor, Kerry
    Owen, Carolyn
    Johnson, David Michael
    Aiello, Maria
    Dansey, Roger D.
    Dubowy, Ronald L.
    Jones, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB (IDELA) IN COMBINATION WITH OFATUMUMAB (OFA) FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Robak, T.
    Wach, M.
    Jones, J. A.
    Owen, C.
    Brown, J. R.
    Menter, A. R.
    Ysebaert, L.
    Wagner-Johnston, N.
    Awan, F.
    Taylor, K.
    Schuh, A.
    Cannell, P.
    Morris, K.
    Larratt, L.
    Skotnicki, A.
    Loscertales, J.
    Nathwani, A.
    Badoux, X.
    Hahn, U.
    Pulczynski, E. Jacobsen
    Feugier, P.
    Zini, J. -M.
    Dihuydy, M. -S.
    Sanhes, L.
    Garcia-Marco, J. A.
    Bosch, F.
    Dreiling, L.
    Peterman, S.
    Cho, Y.
    Dubowy, R.
    Vandenberghe, E.
    HAEMATOLOGICA, 2015, 100 : 229 - 229
  • [5] Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib in combination with ofatumumab (OFA) for previously treated patients with CLL
    Jones, J. Alan
    Wach, M.
    Robak, T.
    Brown, J.
    Menter, A.
    Vandenberghe, E.
    Ysebaert, L.
    Wagner-Johnston, N.
    Polikoff, J.
    Salman, H.
    Taylor, K. M.
    Coutre, S.
    Spurgeon, S. E. F.
    Kendall, S.
    Flinn, I.
    Dreiling, L.
    Dubowy, R.
    Cho, Y.
    Peterman, S.
    Owen, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 98 - 98
  • [6] Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
    Danilov, Alexey V.
    Herbaux, Charles
    Walter, Harriet S.
    Hillmen, Peter
    Rule, Simon A.
    Kio, Ebenezer A.
    Karlin, Lionel
    Dyer, Martin J. S.
    Mitra, Siddhartha S.
    Yi, Ping Cheng
    Humeniuk, Rita
    Huang, Xi
    Zhou, Ziqian
    Bhargava, Pankaj
    Jurgensmeier, Juliane M.
    Fegan, Christopher D.
    CLINICAL CANCER RESEARCH, 2020, 26 (12) : 2810 - 2818
  • [7] A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)
    Chen, Christine I.
    Snitzler, Susi
    Levina, Olga
    Wang, Tong
    Le, Lisa W.
    Paul, Harminder
    Wei, Ellen Nong
    Lau, Anthea
    Queau, Michelle
    Johnston, James B.
    Trudel, Suzanne
    Smith, Deborah A.
    BLOOD, 2015, 126 (23)
  • [8] Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results From the Randomized Phase III RESONATE™ (PCYC-1112) Trial
    Brown, J. Jennifer R.
    Byrd, John C.
    O'Brien, Susan
    Barrientos, Jacqueline C.
    Kay, Neil E.
    Reddy, Nishitha M.
    Coutre, Steven
    Tam, Constantine S.
    Mulligan, Stephen
    Jaeger, Ulrich
    Devereux, Stephen
    Barr, Paul M.
    Furman, Richard
    Kipps, Thomas
    Cymbalista, Florence
    Fardis, Maria
    McGreivy, Jesse
    Clow, Fong
    James, Danelle F.
    Hilmen, Peter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S204 - S204
  • [9] A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
    Eradat, Herbert Aaron
    Coutre, Steven E.
    Barrientos, Jacqueline Claudia
    Rai, Kanti Roop
    Farber, Charles Michael
    Hillmen, Peter
    Sharman, Jeff Porter
    Ghia, Paolo
    Coiffier, Bertrand
    Walewski, Jan Andrzej
    Berneman, Zwi N.
    O'Brien, Susan Mary
    Brown, Jennifer R.
    Peterman, Sissy
    Dansey, Roger D.
    Jahn, Thomas Michael
    Cramer, Paula
    Hallek, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*
    Chen, Christine I.
    Paul, Harminder
    Le, Lisa W.
    Wei, Ellen N.
    Snitzler, Susi
    Wang, Trina
    Levina, Olga
    Kakar, Sumeet
    Lau, Anthea
    Queau, Michelle
    Johnston, James B.
    Smith, Deborah A.
    Trudel, Suzanne
    LEUKEMIA & LYMPHOMA, 2019, 60 (01) : 92 - 100
12345